Indirect comparisons between data from clinical trials of TRK inhibitors and the real-world assessment presented here support the hypothesis that OS in patients with NTRK+ solid tumors may be considerably improved by treatment with TRK inhibitors versus the current SoC, supporting the need for broader testing of targetable oncogenic biomarkers and the selection of the most appropriate therapy based on the tumor’s molecular profile. The gene discussed is NTRK1; the disease is neoplasm.